Erbay İlke, Avcı Rabia Hande, Eriş Güdül Naile, Altuntaş Murat, Süner Ahmet Furkan, Aladağ Pelin, Köktürk Uğur, Avcı Ahmet
Department of Cardiology, Bülent Ecevit University Faculty of Medicine, Zonguldak, Türkiye.
Department of Pulmonology, Karabuk University Training and Research Hospital, Karabük, Türkiye.
Anatol J Cardiol. 2025 May 29;29(8):423-30. doi: 10.14744/AnatolJCardiol.2025.5195.
Obstructive sleep apnea (OSA) is associated with increased cardiovascular risk, particularly through right ventricular (RV) dysfunction. Cancer antigen 125 (CA125), a biomarker traditionally used in ovarian cancer, has shown potential as an indicator of RV dysfunction. This study aims to compare CA125 levels between OSA patients and controls and to evaluate its association with disease severity and subclinical RV dysfunction.
This cross-sectional study included sixty OSA patients, divided into severe (apnea-hypopnea index [AHI] ≥ 30) and non-severe groups, and sixty age- and sex-matched controls. Cancer antigen 125 levels were assessed together with echocardiographic markers. Regression analysis identified predictors of severe OSA, and receiver operating characteristic (ROC) analysis assessed the diagnostic performance of CA125.
Cancer antigen 125 levels were significantly elevated in severe OSA patients compared to non-severe and control groups (median 34.3 vs. 12.9 vs. 10.3 U/mL, P < .001). Cancer antigen 125 correlated with RV fractional area change (RV-FAC) (r = -0.496, P < .001), tricuspid annular plane systolic excursion (TAPSE) (r = -0.285, P = .027), and AHI (r = 0.581, P < .001). Regression analysis identified CA125 (odds ratio [OR] = 1.259, 95% con-fidence interval [CI]: 1.102-1.438, P = .001) and TAPSE (OR= 0.425, 95% CI: 0.217-0.834, P = .013) as independent predictors of severe OSA. ROC analysis showed that CA125 could effectively predict RV dysfunction (area under the curve [AUC] = 0.857) and severe OSA (AUC = 0.804).
Elevated CA125 levels are associated with increased disease severity and subclinical RV dysfunction in OSA, suggesting its potential as a biomarker for early cardiac involvement.
阻塞性睡眠呼吸暂停（OSA）与心血管风险增加相关，尤其是通过右心室（RV）功能障碍。癌抗原125（CA125）是一种传统上用于卵巢癌的生物标志物，已显示出作为RV功能障碍指标的潜力。本研究旨在比较OSA患者和对照组之间的CA125水平，并评估其与疾病严重程度和亚临床RV功能障碍的关联。
这项横断面研究纳入了60例OSA患者，分为重度组（呼吸暂停低通气指数[AHI]≥30）和非重度组，以及60例年龄和性别匹配的对照组。评估癌抗原125水平以及超声心动图标志物。回归分析确定重度OSA的预测因素，受试者工作特征（ROC）分析评估CA125的诊断性能。
与非重度组和对照组相比，重度OSA患者的癌抗原125水平显著升高（中位数34.3 vs. 12.9 vs. 10.3 U/mL，P <.001）。癌抗原125与RV面积变化分数（RV-FAC）（r = -0.496，P <.001）、三尖瓣环平面收缩期位移（TAPSE）（r = -0.285，P =.027）和AHI（r = 0.581，P <.001）相关。回归分析确定CA125（比值比[OR]=1.259，95%置信区间[CI]：1.102 - 1.438，P =.001）和TAPSE（OR = 0.425，95% CI：0.217 - 0.834，P =.013）为重度OSA的独立预测因素。ROC分析表明，CA125可有效预测RV功能障碍（曲线下面积[AUC]=0.857）和重度OSA（AUC = 0.804）。
CA125水平升高与OSA患者疾病严重程度增加和亚临床RV功能障碍相关，表明其作为早期心脏受累生物标志物的潜力。
